Endo International says it intends to expedite a cost-saving plan by closing a manufacturing site in North Carolina and reducing headcount at another in Alabama.
VistaPharm has recalled thousands of cases of generic oxycodone as a result of a defect that allowed the powerful painkiller to leak out of the packaging.
The US Government is set to extend an anthrax vaccine supply contract, and Emergent Biosolutions believes its new commercial-scale facility coming online was a driving factor.
A remediation plan by Medreich Limited is sufficient to bring its Andhra Pradesh antibiotics plant in to compliance with GMP according to French regulator ANSM.
Drug companies will prioritize the EU over the UK in the event of Brexit according to the ABPI, which says members recognize the benefits of centralised licensing.
Inadequate record keeping at Merck & Co.’s contract manufacturer has delayed the European launch of its hepatitis C drug Zepatier (elbasvir and grazoprevir).
Mass Innovation Labs is working to change the way biopharmaceutical companies conduct research by providing a “crossroads” for CRO service providers, vendors, and investors.
The merger combines the two companies’ data sets in order to expedite clinical trials and has the potential to send “shockwaves” through the industry, says ISR president.
Marken has announced an expansion of its third party service providers and customs brokers network to prepare for a “significant’ increase in drug, vaccine, API, and ancillary shipment volumes.
Parexel has announced its financial results for the third quarter of FY16, which remained strong in spite of the complexities associated with smaller clinical trials.
As the company tries to move out from under Shkreli's cloud, KaloBios has announced a new product pricing model that promises transparency, affordably, and reasonable return.
Quintiles and IMS Health have merged to form Quintiles IMS Holdings, effectively creating one of the world’s largest healthcare information portfolios.
Next week, sponsors and CROs will gather in Princeton, New Jersey to discuss how integrating quality, innovation and collaboration can transform the clinical trial process, bringing medicines to patients in a more expedited manner.
Increased use of generics has put pressure on drug reviewers according to the EDQM which has called for more cross border collaboration and harmonization of regulations.
As a significant amount of drug discoveries occur outside of pharma companies, Elsevier has launched The Hive Project to promote innovation in the market – outside its walls.
The US FDA has modified a 2013 consent decree issued to Ben Venue Laboratories, paving the way for new owners Xellia Pharmaceuticals to resume manufacturing at the dormant Ohio site.
An API facility Cambrex is setting up in Charles City, Iowa will be operational later than planned due to delayed equipment deliveries and installation challenges.
Full production at Catalent’s Beinheim softgel plant has begun five months after the discovery of out-of-place capsules led to French regulators suspending operations.
Indian firm Polydrug Laboratories failed to investigate complaints about APIs containing foreign bodies including hairs and insects, the US FDA says in a Warning Letter.
AstraZeneca will supply Ironwood Pharmaceuticals with the API and finished dosage form of the gout drug Zurampic under the licensing deal agreed this week.
Lonza plans to expand mammalian cell culture-based drug and viral manufacturing capacity after growth in both businesses helped it to record first quarter sales.
Fette Compacting has unveiled its first capsule filling machine, which is capable of outputting 400,000 capsules per hour – a new record in the industry.
3D printing can make drug production simpler and cheaper according to a UK expert who says using it for commercial production is about “numbering up” not scaling up.
Regulations, recruitment and facility refits are holding continuous manufacturing back, but a Rutgers’ associate behind J&J’s recent success believes industry can overcome these hurdles.
